🚨Our June issue is LIVE🚨 Our annual #Pharma50 issue is BIGGER THAN EVER🔷Mark Cuban speaks about #drugpricing, transparency, and Mark Cuban Cost Plus Drug Company, PBC🔷The 24th listing of ur top 50 #pharma companies🔷How we should respond to the changing #healthcare system🔷and so much more, right here ➡️ https://lnkd.in/em4irY_R
Pharmaceutical Executive
Book and Periodical Publishing
Iselin, New Jersey 25,267 followers
Master the Science of Success
About us
Pharmaceutical Executive provides its audience of pharmaceutical and biopharmaceutical executives with the analysis of business, strategy, and government regulations. We go beyond the news and provide in-depth analysis to help executives navigate through the maze of policy and business challenges that face this industry. We do it through the review of the issues, interviews, and roundtable discussions with thought leaders and business leaders.
- Website
-
http://www.pharmexec.com/
External link for Pharmaceutical Executive
- Industry
- Book and Periodical Publishing
- Company size
- 11-50 employees
- Headquarters
- Iselin, New Jersey
- Type
- Privately Held
- Specialties
- Publishing, Pharmaceutical News, and Biopharmaceutical News
Locations
-
Primary
Iselin, New Jersey 07072, US
-
2 Penn Plaza
15th Floor
New York, NY 07072, US
Employees at Pharmaceutical Executive
Updates
-
Pharmaceutical Executive reposted this
-
IDN Trends, Insights and Strategies Every Manufacturer Should Know Join industry experts at our live webcast with EVERSANA! Gain insights from Faruk Abdullah, Matt Wilkins, and KRISTA PINTO as they dive into the latest trends shaping the Integrated Delivery Networks (IDN) market, from consolidation to the shift towards value-based care. Discover effective strategies for building and maintaining strong partnerships with IDNs. Register now: https://lnkd.in/g6stsas5
-
-
Insights from Takeda, Jazz Pharmaceuticals, Nestlé Health Science, Humana, and other healthcare executives🖋️ Tracy Duberman, PhD, MPH, FACHE, PhD, President and CEO, TLD Group (The Leadership Development Group)
Talent Management Strategies for Post-Milestone Growth
pharmexec.com
-
Pharmaceutical Executive reposted this
Artificial intelligence and data have the potential to merge seamlessly to build a whole-person health program, but it’s crucial to address bias from the outset. Avalere Health CEO Jon Koch discusses the journey to whole-person health and how the right partners can support you in this interview with Pharmaceutical Executive: https://bit.ly/3S3FwHF
-
-
Pharmaceutical Executive reposted this
According to Matt Erick, Chief Commercial Officer of Advanced Markets at Biocon Biologics: "To harness the potential of biosimilars to promote more equitable competition, decrease costs and improve access for patients, we must implement a biosimilars-first approach that incentivizes healthcare providers and payers to take advantage of the potential cost savings of biosimilars at launch." Despite a slow start, experts predict 2024 to be a significant year for the biosimilars market. Read Matt's interview on Pharmaceutical Executive to hear his insight into the current state of the market and how it may change in the coming months: https://lnkd.in/g2WSed9p #Biosimilars #Lifesciences #Research #BiosimilarMedicine #ExecutiveSearch #BecauseTalentMatters
The Future of Biosimilars: Q&A with Matt Erick
pharmexec.com
-
Pharmaceutical Executive reposted this
By prioritizing multicultural considerations and embracing inclusive communication, we can achieve better patient outcomes and reduce health disparities. Learn how medical professionals can foster meaningful connections and trust in our latest article by Fingerpaint Multicultural and MedThink SciCom, a Fingerpaint Group Company, exclusively in Pharmaceutical Executive: https://bit.ly/46quvGb #HealthEquity #CulturalCompetence #InclusiveHealthcare #InclusiveCommunication
-
-
Biocon Biologics’ chief commercial officer of advanced markets, Matt Erick, discusses the current market and potential trends for #biosimilars 💬🗨️ Michael Hollan
The Future of Biosimilars: Q&A with Matt Erick
pharmexec.com